Amgen Inc. $AMGN Stock Position Increased by Johnson & White Wealth Management LLC

Johnson & White Wealth Management LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,199 shares of the medical research company’s stock after purchasing an additional 129 shares during the period. Johnson & White Wealth Management LLC’s holdings in Amgen were worth $614,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Patton Albertson Miller Group LLC grew its holdings in shares of Amgen by 2.4% during the second quarter. Patton Albertson Miller Group LLC now owns 4,013 shares of the medical research company’s stock valued at $1,120,000 after buying an additional 95 shares in the last quarter. Tritonpoint Wealth LLC lifted its position in shares of Amgen by 5.8% during the 2nd quarter. Tritonpoint Wealth LLC now owns 1,934 shares of the medical research company’s stock worth $540,000 after purchasing an additional 106 shares during the last quarter. Stone Summit Wealth LLC lifted its position in shares of Amgen by 5.6% during the 2nd quarter. Stone Summit Wealth LLC now owns 1,835 shares of the medical research company’s stock worth $512,000 after purchasing an additional 97 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its position in shares of Amgen by 1.1% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 84,530 shares of the medical research company’s stock worth $23,602,000 after purchasing an additional 883 shares during the last quarter. Finally, Guardian Investment Management lifted its position in shares of Amgen by 2.7% during the 2nd quarter. Guardian Investment Management now owns 18,695 shares of the medical research company’s stock worth $5,220,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN stock opened at $272.98 on Friday. The business’s fifty day moving average is $288.86 and its 200-day moving average is $289.06. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The company has a market cap of $146.96 billion, a P/E ratio of 22.32, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were issued a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a dividend yield of 3.5%. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.76% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AMGN shares. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Bank of America upped their price objective on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday. UBS Group lowered their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Finally, Raymond James Financial initiated coverage on Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating on the stock. Seven investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $309.70.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.